Pacira Pharmaceuticals, Inc.
) announced that results from the IMPROVE study on its marketed
product Exparel was published in the journal
The IMPROVE studies are evaluating the differences in
postsurgical opioid use and health economic outcomes between
patients with laparoscopic colectomy receiving Exparel and those
on a standard opioid-based analgesic regimen.
The open-label, phase IV study under the IMPROVE program
(n=82) was conducted among patients who underwent laparoscopic
colectomy to remove all or part of the colon using several small
incisions in the abdomen. Of the 82 patients, 26 were enrolled in
the Exparel-based multimodal group. The remaining patients were
enrolled in the opioid-based intravenous (IV) patient-controlled
analgesia (PCA) arm.
Results from the study revealed a 1-day reduction in the
median length of hospital stay, $1,784 reduction in mean
hospitalization costs and 64 mg reduction in mean opioid
consumption in patients under the Exparel group compared to the
opioid-based treatment arm.
Exparel is currently approved by the U.S. Food and Drug
Administration (FDA) for administration into the surgical site to
produce post-surgical analgesia. The drug was launched in Apr
In the first nine months of 2013, net Exparel revenues were
$45.6 million. At the end of Sep 2013, Exparel had a customer
base of 1,732. Pacira reported an average of 23 new customers per
week in the reported quarter.
Pacira carries a Zacks Rank #4 (Sell). Other better-ranked
players in the pharma industry include
Sucampo Pharmaceuticals Inc.
PharmaTech (Cayman) Inc.
Forest Laboratories Inc.
). All the three stocks carry a Zacks Rank #1 (Strong Buy).
FOREST LABS A (FRX): Free Stock Analysis
PACIRA PHARMACT (PCRX): Free Stock Analysis
SUCAMPO PHARMAC (SCMP): Free Stock Analysis
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.